Literature DB >> 12198151

Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function.

Shih-Shun Chen1, Pi-Chu Chang, Yu-Wen Cheng, Fen-Mei Tang, Young-Sun Lin.   

Abstract

Using a transactivation-defective p53 derivative as bait, STK15, a centrosome-associated oncogenic serine/threonine kinase, was isolated as a p53 partner. The p53-STK15 interaction was confirmed further by co-immunoprecipitation and GST pull-down studies. In co-transfection experiments, p53 suppressed STK15-induced centrosome amplification and cellular transformation in a transactivation-independent manner. The suppression of STK15 oncogenic activity by p53 might be explained in part by the finding that p53 inhibited STK15 kinase activity via direct interaction with the latter's Aurora box. Taken together, these findings revealed a novel mechanism for the tumor suppressor function of p53.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198151      PMCID: PMC126178          DOI: 10.1093/emboj/cdf409

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  49 in total

1.  Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo.

Authors:  C Gaiddon; N C Moorthy; C Prives
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

2.  p53 localizes to the centrosomes and spindles of mitotic cells in the embryonic chick epiblast, human cell lines, and a human primary culture: An immunofluorescence study.

Authors:  V B Morris; J Brammall; J Noble; R Reddel
Journal:  Exp Cell Res       Date:  2000-04-10       Impact factor: 3.905

3.  Antagonism between members of the CNC-bZIP family and the immediate-early protein IE2 of human cytomegalovirus.

Authors:  C F Huang; Y C Wang; D A Tsao; S F Tung; Y S Lin; C W Wu
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

Review 4.  p53 regulation by post-translational modification and nuclear retention in response to diverse stresses.

Authors:  G S Jimenez; S H Khan; J M Stommel; G M Wahl
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

5.  Centrosome multiplication accompanies a transient clustering of polyploid cells during tissue repair.

Authors:  M Oberringer; D Lothschütz; M Jennewein; M Koschnick; W Mutschler; R G Hanselmann
Journal:  Mol Cell Biol Res Commun       Date:  1999 Sep-Dec

Review 6.  The complexity of p53 modulation: emerging patterns from divergent signals.

Authors:  A J Giaccia; M B Kastan
Journal:  Genes Dev       Date:  1998-10-01       Impact factor: 11.361

7.  c-abl is involved in the association of p53 and trk A.

Authors:  A Brown; C Browes; M Mitchell; X Montano
Journal:  Oncogene       Date:  2000-06-15       Impact factor: 9.867

8.  A transactivation-deficient mouse model provides insights into Trp53 regulation and function.

Authors:  G S Jimenez; M Nister; J M Stommel; M Beeche; E A Barcarse; X Q Zhang; S O'Gorman; G M Wahl
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

9.  Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.

Authors:  H C Kirch; S Flaswinkel; H Rumpf; D Brockmann; H Esche
Journal:  Oncogene       Date:  1999-04-29       Impact factor: 9.867

Review 10.  Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases.

Authors:  R Giet; C Prigent
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

View more
  30 in total

1.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

Review 2.  Aurora kinases in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Barbara Burtness; Igor Astsaturov; Erica A Golemis
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

3.  Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation.

Authors:  Jennifer Y Pan; Jaffer A Ajani; Jian Gu; Yubo Gong; Angel Qin; Angel Quin; Maosheng Hung; Xifeng Wu; Julie G Izzo
Journal:  Cancer       Date:  2011-12-27       Impact factor: 6.860

Review 4.  Issues in interpreting the in vivo activity of Aurora-A.

Authors:  Elena Shagisultanova; Roland L Dunbrack; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2014-11-11       Impact factor: 6.902

5.  Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A.

Authors:  Laurie E Littlepage; Hua Wu; Thorkell Andresson; Julia K Deanehan; Laufey T Amundadottir; Joan V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-06       Impact factor: 11.205

6.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

7.  MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-mesenchymal transdifferentiation.

Authors:  Chun-Fu Hong; Yu-Ting Chou; Young-Sun Lin; Cheng-Wen Wu
Journal:  J Biol Chem       Date:  2009-05-14       Impact factor: 5.157

8.  Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.

Authors:  Mauro Siragusa; William C Sessa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

9.  Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora.

Authors:  Eunice H Y Chan; Anna Santamaria; Herman H W Silljé; Erich A Nigg
Journal:  Chromosoma       Date:  2008-06-03       Impact factor: 4.316

Review 10.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.